Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate
Abstract
Objective To describe clinically relevant effects of lisdexamfetamine dimesylate (LDX) on emotional expression (EE) in children with ADHD. Method Children with ADHD participated in a 7-week, open-label, LDX dose-optimization study. Expression and Emotion Scale for Children (EESC) change scores were analyzed post hoc using two methods to determine proportion of participants with different categories of clinical response based on (a) clinically significant (movement >2 SD from baseline mean)/reliable change (not due to measurement error) and (b) standard error of measurement (SEM) as a measure of clinically meaningful change. Results With LDX, no participants showed clinically significant/reliable improvement; 0.7% showed clinically significant/reliable deterioration of EE by reliable change index and movement from baseline mean. One third of participants had improved EE by SEM criteria; 9.2% had categorical worsening. Conclusion Using clinically meaningful change and clinically significant/reliable change categories derived from the EESC, most participants had no worsening of EE with LDX.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The original study was limited by exclusion of patients with psychiatric comorbidity.
“However, it should be noted that the original study was limited by exclusion of patients with psychiatric comorbidity.”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [36]
More participants were categorized as improved than worsened based on EESC score change from baseline.
“However, more participants were categorized as improved, with an end of study/early termination (EOS/ET) score ≤1 standard error of measurement (SEM) of baseline score, than were categorized as worsened, with an EOS/ET score ≥1 SEM of baseline score.”
From Treatment Outcomes with Lisdexamfetamine Dimesylate in Children Who Have Attention-Deficit/Hyperactivity Disorder with Emotional Control Impairments (2013) · cites this paper as Katic et al. 2012
The majority of participants showed no meaningful change in EESC scores.
“The majority of participants showed no meaningful change in EESC scores.”
From Treatment Outcomes with Lisdexamfetamine Dimesylate in Children Who Have Attention-Deficit/Hyperactivity Disorder with Emotional Control Impairments (2013) · cites this paper as Katic et al. 2012
In a further post-hoc analysis of EESC findings, LDX treatment was not associated with overall clinical worsening of emotional expression in most children.
“In a further post-hoc analysis of EESC findings, LDX treatment was not associated with overall clinical worsening of emotional expression in most children (Katic et al. 2012).”
From Treatment Outcomes with Lisdexamfetamine Dimesylate in Children Who Have Attention-Deficit/Hyperactivity Disorder with Emotional Control Impairments (2013) · cites this paper as Katic et al. 2012
In a post-hoc analysis of EESC data sets based on the Jacobson and Truax method, at least 99% of participants did not show emotional control impairments and method-defined, reliable change in emotional expression during LDX treatment.
“In a post-hoc analysis of EESC data sets based on the Jacobson and Truax method (Jacobson and Truax 1991), ≥99% of participants did not show emotional control impairments and method-defined, reliable change in emotional expression during LDX treatment (Katic et al. 2012).”
From Treatment Outcomes with Lisdexamfetamine Dimesylate in Children Who Have Attention-Deficit/Hyperactivity Disorder with Emotional Control Impairments (2013) · cites this paper as Katic et al. 2012
Cites
Safety and tolerability of methylphenidate in preschool children with ADHD
WIGAL, T., GREENHILL, L., CHUANG, S., McGOUGH, J., VITIELLO, B., SKROBALA, A., SWANSON, J., WIGAL, S., ABIKOFF, H., KOLLINS, S., et al. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000235082.63156.27 · Cited by 242 · see citing works
Placebo-Controlled Evaluation of Ritalin Side Effects
Ahmann, P. A., Waltonen, S. J., Theye, F. W., Olson, K. A., & Van Erem, A. J. (1993) · Pediatrics · doi:10.1542/peds.91.6.1101 · Cited by 178 · cited 2× · see citing works
“Stimulants have been variously reported to both improve and cause worsening of symptoms of emotional lability (Ahmann et al., 1993; Gillberg et al., 1997; Short et al., 2004).”
BackgroundAbsorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170 · see citing works
the 311 Study Group, Wigal, S. B., Kollins, S. H., Childress, A. C., & Squires, L. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-17 · Cited by 112 · see citing works
Stimulant Rebound: How Common Is It and What Does It Mean?
Carlson, G. A., & Kelly, K. L. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322163853 · Cited by 76 · see citing works
Silva, R. R., Muniz, R., Pestreich, L., Childress, A., Brams, M., Lopez, F. A., & Wang, J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.239 · Cited by 44 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Childress, A. C., Arnold, V., Adeyi, B., Dirks, B., Babcock, T., Scheckner, B., Lasser, R., & Lopez, F. A. (2014) · Journal of Attention Disorders · doi:10.1177/1087054712448252 · Cited by 33 · see citing works
Self-citationUpdate on optimal use of lisdexamfetamine in the treatment of ADHD
Madaan, V., Kolli, V., Bestha, D., & Shah, M. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s34092 · Cited by 19 · see citing works
“In a post hoc analysis of this 7-week, open-label lisdexamfetamine study, Katic et al 36 used the clinically meaningful change and clinically significant/ reliable change categories derived from the EESC to show that there was no deterioration in emotional expression in a majority of subjects when taking lisdexamfetam…”
Katic, A., Dirks, B., Babcock, T., Scheckner, B., Adeyi, B., Richards, C., & Findling, R. L. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0104 · Cited by 10 · see citing works
Self-citation
- Authors
- Katic, A., Ginsberg, L., Jain, R., Adeyi, B., Dirks, B., Babcock, T., Scheckner, B., Richards, C., Lasser, R., Turgay, A., & Findling, R. L.
- Affiliations
- Claghorn Lesem Research Clinic (US)
- Red Oak Psychiatry Associates, P.A., Houston, TX
- Clinical Research Puerto Rico (PR)
- Takeda (United States) (US)
- University of Toronto (CA)
- University Hospitals Cleveland Medical Center (US)
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2010-12-20
- Volume
- 16
- Issue
- 5
- Pages
- 384-397
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2082691922
- Cited by
- 10
- References
- 6
- Citations by year
- 2020: 1 · 2019: 2 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 3
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Attention Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, emotional expression, children, reliable change index, standard error of measurement, clinically meaningful change, dose optimization, stimulant medication
- MeSH terms
- Lisdexamfetamine Dimesylate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Dextroamphetamine, Dose-Response Relationship, Drug, Emotions, Female, Humans, Male, Psychiatric Status Rating Scales, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
